VIM and ovarian carcinoma: In the current study, we first established a cell model of TGF-β1-induced ovarian cancer cell EMT and found that sorafenib was able to increase the protein level of E-cadherin and suppress the protein expression of vimentin, indicating that sorafenib reversed the effect of TGF-β1.